Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for r… Read more
Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt (LGNZZ) - Total Assets
Latest total assets as of June 2025: $1.48 Billion USD
Based on the latest financial reports, Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt (LGNZZ) holds total assets worth $1.48 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt - Total Assets Trend (2000–2024)
This chart illustrates how Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt - Asset Composition Analysis
Current Asset Composition (December 2024)
Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt's total assets of $1.48 Billion consist of 35.2% current assets and 64.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.7% |
| Accounts Receivable | $38.38 Million | 4.1% |
| Inventory | $14.11 Million | 1.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $266.65 Million | 28.3% |
| Goodwill | $105.25 Million | 11.2% |
Asset Composition Trend (2000–2024)
This chart illustrates how Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt's current assets represent 35.2% of total assets in 2024, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 7.7% of total assets in 2024, up from 0.0% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 39.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is intangible assets at 28.3% of total assets.
Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt Competitors by Total Assets
Key competitors of Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt generates 0.18x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt generates $ 0.96 in net profit.
Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 24.69 | 16.82 | 20.28 |
| Quick Ratio | 24.30 | 15.70 | 19.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $723.38 Million | $ 293.69 Million | $ 815.44 Million |
Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt - Advanced Valuation Insights
This section examines the relationship between Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 19.6% |
| Total Assets | $941.77 Million |
| Market Capitalization | $2.70 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt's assets grew by 19.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt (2000–2024)
The table below shows the annual total assets of Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $941.77 Million | +19.63% |
| 2023-12-31 | $787.22 Million | +3.22% |
| 2022-12-31 | $762.67 Million | -41.22% |
| 2021-12-31 | $1.30 Billion | -4.75% |
| 2020-12-31 | $1.36 Billion | -8.87% |
| 2019-12-31 | $1.49 Billion | +13.87% |
| 2018-12-31 | $1.31 Billion | +81.66% |
| 2017-12-31 | $722.65 Million | +20.12% |
| 2016-12-31 | $601.59 Million | +19.58% |
| 2015-12-31 | $503.06 Million | +1713.36% |
| 2008-12-31 | $27.74 Million | -44.65% |
| 2007-12-31 | $50.12 Million | -41.62% |
| 2006-12-31 | $85.86 Million | +16.21% |
| 2005-12-31 | $73.88 Million | +54.36% |
| 2004-12-31 | $47.86 Million | +64.41% |
| 2003-12-31 | $29.11 Million | +33.94% |
| 2002-12-31 | $21.73 Million | -23.58% |
| 2001-12-31 | $28.44 Million | +106.07% |
| 2000-12-31 | $13.80 Million | -- |